Bell,sons & Co.(druggists)limited

POWER SEARCH PRICING

SOLUTIONS

bell,sons & co.(druggists)limited Company Information

Live

MatureLargeHealthy

Company Number

00351951

Website

http://bells-healthcare.com

Registered Address

gifford house slaidburn crescent, southport, merseyside, PR9 9AL

Industry

Manufacture of basic pharmaceutical products

Telephone

01514221200

Next Accounts Due

December 2025

Group Structure

View All

Directors

Mark Saldanha16 Years

Sathish Konasagar Jayanna7 Years

View All

Shareholders

marksans holdings limited 100%

bell,sons & co.(druggists)limited Estimated Valuation

£115m

Pomanda estimates the enterprise value of BELL,SONS & CO.(DRUGGISTS)LIMITED at £115m based on a Turnover of £53.7m and 2.14x industry multiple (adjusted for size and gross margin).

Edit your figures and get a professional valuation report.

Bell,sons & Co.(druggists)limited is a live company located in merseyside, PR9 9AL with a Companies House number of 00351951. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in April 1939, it's largest shareholder is marksans holdings limited with a 100% stake. Bell,sons & Co.(druggists)limited is a mature, large sized company, Pomanda has estimated its turnover at £53.7m with healthy growth in recent years.

View Sample

Upgrade for unlimited company reports & a free credit check

Pomanda's financial health check has awarded Bell,Sons & Co.(Druggists)Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 7 measures and has 2 areas for improvement. Company Health Check FAQs

Health Rating5out of 5

7 Strong

3 Regular

2 Weak

Size

annual sales of £53.7m, make it larger than the average company (£28.9m)

Growth

3 year (CAGR) sales growth of 11%, show it is growing at a faster rate (5.5%)

EXPORT

Bell,Sons & Co.(Druggists)Limited's latest turnover from March 2024 is £53.7 million and the company has net assets of £26 million. According to their latest financial statements, Bell,Sons & Co.(Druggists)Limited has 204 employees and maintains cash reserves of £7.1 million as reported in the balance sheet.

Data source: Companies House, Pomanda Estimates

	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010
Turnover	53,652,924	45,768,318	36,293,092	38,778,680	32,940,253	22,119,801	18,021,449	15,984,125	18,516,229	19,419,682	16,911,972	15,541,954	13,970,880	11,292,001	10,530,536
Other Income Or Grants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cost Of Sales	42,760,035	37,719,365	28,564,544	25,148,996	26,628,176	18,769,081	15,389,477	13,498,286	15,396,938	16,112,200	14,411,955	12,959,990	11,861,504	9,608,842	8,851,320
Gross Profit	10,892,889	8,048,953	7,728,548	13,629,684	6,312,077	3,350,720	2,631,972	2,485,839	3,119,291	3,307,482	2,500,017	2,581,964	2,109,376	1,683,159	1,679,216
Admin Expenses	3,310,616	3,110,177	2,730,622	2,912,644	2,531,831	2,555,691	2,343,745	2,268,100	2,476,702	1,629,712	1,413,534	1,490,460	1,327,595	1,318,692	1,228,280
Operating Profit	7,582,273	4,938,776	4,997,926	10,717,040	3,780,246	795,029	288,227	217,739	642,589	1,677,770	1,086,483	1,091,504	781,781	364,467	450,936
Interest Payable	0	0	1,146	9,079	81,341	153,533	154,313	162,989	162,925	154,537	155,695	160,327	169,918	137,829	60,893
Interest Receivable	0	0	0	0	0	5,027	72,138	800	486	683	573	366	233	271	15,236
Pre-Tax Profit	7,588,182	4,917,810	4,996,780	10,707,961	3,698,905	641,496	133,914	54,750	480,150	1,523,916	931,361	931,543	612,096	226,909	405,279
Tax	-2,077,522	-936,057	-1,034,495	-2,042,939	-810,932	-105,857	-24,824	0	-60,983	-332,709	-187,040	-173,039	-14,140	1,363	-8,591
Profit After Tax	5,510,660	3,981,753	3,962,285	8,665,022	2,887,973	535,639	109,090	54,750	419,167	1,191,207	744,321	758,504	597,956	228,272	396,688
Dividends Paid	1,250,000	1,250,000	600,000	500,000	1,000,000	0	0	0	0	3,000,000	3,000,000	0	0	0	0
Retained Profit	4,260,660	2,731,753	3,362,285	8,165,022	1,887,973	535,639	109,090	54,750	419,167	-1,808,793	-2,255,679	758,504	597,956	228,272	396,688
Employee Costs	6,762,695	5,244,538	4,252,954	4,613,455	4,285,691	3,939,043	3,795,880	3,797,852	4,200,787	3,983,714	3,795,175	3,868,563	3,451,769	2,970,080	2,658,877
Number Of Employees	204	187	163	166	169	152	148	159	176	174	175	157	144	133	134
EBITDA*	7,953,367	5,299,640	5,401,376	11,037,505	4,092,555	1,068,629	500,094	452,568	834,145	1,856,696	1,304,270	1,290,839	995,467	586,823	662,708

* Earnings Before Interest, Tax, Depreciation and Amortisation

	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010
Tangible Assets	4,824,518	3,529,179	3,362,695	3,315,332	3,024,258	3,120,196	3,035,857	3,102,598	3,205,599	3,052,879	2,886,107	2,975,076	3,119,466	3,249,070	3,288,065
Intangible Assets	3,958	6,217	10,040	13,865	18,004	23,243	16,462	23,613	29,505	35,397	44,124	37,404	24,305	23,925	14,850
Investments & Other	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Debtors (Due After 1 year)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Fixed Assets	4,828,476	3,535,396	3,372,735	3,329,197	3,042,262	3,143,439	3,052,319	3,126,211	3,235,104	3,088,276	2,930,231	3,012,480	3,143,771	3,272,995	3,302,915
Stock & work in progress	12,412,366	8,929,695	7,920,903	9,205,454	4,708,726	7,328,701	5,173,382	3,669,598	3,855,807	3,350,912	2,689,539	2,315,358	2,339,140	2,432,052	2,116,661
Trade Debtors	8,065,748	7,182,153	6,551,443	4,015,595	5,273,998	3,250,659	3,014,956	2,756,199	2,899,589	2,787,174	2,309,039	2,444,969	2,261,552	1,579,226	1,248,129
Group Debtors	3,019,701	3,205,055	3,366,347	2,140,161	1,704,043	1,577,573	1,584,196	1,516,120	1,543,166	1,499,370	3,868,592	6,235,532	5,620,626	4,900,621	3,806,876
Misc Debtors	718,075	539,957	172,117	353,943	126,285	323,976	75,155	87,468	73,720	70,496	78,012	68,084	94,785	35,496	142,545
Cash	7,083,255	7,516,546	4,165,761	4,238,533	2,803,006	1,084,878	934,920	1,002,953	751,458	550,383	575,222	981,062	228,635	470,566	288,170
misc current assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
total current assets	31,299,145	27,373,406	22,176,571	19,953,686	14,616,058	13,565,787	10,782,609	9,032,338	9,123,740	8,258,335	9,520,404	12,045,005	10,544,738	9,417,961	7,602,381
total assets	36,127,621	30,908,802	25,549,306	23,282,883	17,658,320	16,709,226	13,834,928	12,158,549	12,358,844	11,346,611	12,450,635	15,057,485	13,688,509	12,690,956	10,905,296
Bank overdraft	0	0	0	98,699	317,003	2,327,460	2,987,651	3,111,180	3,356,152	3,105,390	3,248,851	3,176,397	2,954,004	3,216,021	2,315,134
Bank loan	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Trade Creditors	2,057,327	2,524,239	1,294,259	1,616,059	1,950,748	2,509,364	2,049,422	2,033,325	1,549,928	1,779,186	1,314,720	1,987,050	1,642,928	1,412,483	981,071
Group/Directors Accounts	3,293,239	2,723,195	1,987,632	1,852,550	4,670,260	5,290,450	3,011,814	1,296,582	1,631,206	1,135,613	900,128	499,515	486,356	193,547	424
other short term finances	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
hp & lease commitments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
other current liabilities	4,268,241	3,649,998	2,996,588	3,939,445	3,067,604	904,817	644,545	685,056	843,902	767,933	667,655	811,199	685,048	492,264	450,571
total current liabilities	9,618,807	8,897,432	6,278,479	7,506,753	10,005,615	11,032,091	8,693,432	7,126,143	7,381,188	6,788,122	6,131,354	6,474,161	5,768,336	5,314,315	3,747,200
loans	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
hp & lease commitments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accruals and Deferred Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
other liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
provisions	526,474	289,690	280,900	148,488	190,085	102,488	102,488	102,488	102,488	102,488	47,700	47,700	57,000	134,939	144,666
total long term liabilities	526,474	289,690	280,900	148,488	190,085	102,488	102,488	102,488	102,488	102,488	47,700	47,700	57,000	134,939	144,666
total liabilities	10,145,281	9,187,122	6,559,379	7,655,241	10,195,700	11,134,579	8,795,920	7,228,631	7,483,676	6,890,610	6,179,054	6,521,861	5,825,336	5,449,254	3,891,866
net assets	25,982,340	21,721,680	18,989,927	15,627,642	7,462,620	5,574,647	5,039,008	4,929,918	4,875,168	4,456,001	6,271,581	8,535,624	7,863,173	7,241,702	7,013,430
total shareholders funds	25,982,340	21,721,680	18,989,927	15,627,642	7,462,620	5,574,647	5,039,008	4,929,918	4,875,168	4,456,001	6,271,581	8,535,624	7,863,173	7,241,702	7,013,430

	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010
Operating Activities
Operating Profit	7,582,273	4,938,776	4,997,926	10,717,040	3,780,246	795,029	288,227	217,739	642,589	1,677,770	1,086,483	1,091,504	781,781	364,467	450,936
Depreciation	368,835	357,041	399,625	316,326	307,070	267,949	206,216	228,937	185,664	170,199	35,931	196,272	210,936	220,431	210,122
Amortisation	2,259	3,823	3,825	4,139	5,239	5,651	5,651	5,892	5,892	8,727	181,856	3,063	2,750	1,925	1,650
Tax	-2,077,522	-936,057	-1,034,495	-2,042,939	-810,932	-105,857	-24,824	0	-60,983	-332,709	-187,040	-173,039	-14,140	1,363	-8,591
Stock	3,482,671	1,008,792	-1,284,551	4,496,728	-2,619,975	2,155,319	1,503,784	-186,209	504,895	661,373	374,181	-23,782	-92,912	315,391	2,116,661
Debtors	876,359	837,258	3,580,208	-594,627	1,952,118	477,901	314,520	-156,688	159,435	-1,898,603	-2,492,942	771,622	1,461,620	1,317,793	5,197,550
Creditors	-466,912	1,229,980	-321,800	-334,689	-558,616	459,942	16,097	483,397	-229,258	464,466	-672,330	344,122	230,445	431,412	981,071
Accruals and Deferred Income	618,243	653,410	-942,857	871,841	2,162,787	260,272	-40,511	-158,846	75,969	100,278	-143,544	126,151	192,784	41,693	450,571
Deferred Taxes & Provisions	236,784	8,790	132,412	-41,597	87,597	0	0	0	0	54,788	0	-9,300	-77,939	-9,727	144,666
Cash flow from operations	1,904,930	4,409,713	938,979	5,588,020	5,641,248	-950,234	-1,367,448	1,120,016	-44,457	3,380,749	2,420,117	830,933	-42,091	-581,620	-5,083,786
Investing Activities
capital expenditure	-1,664,174	-523,525	-446,988	-607,400	-211,132	-364,720	-137,975	-125,936	-338,384	0	-135,538	-68,044	-84,462	-192,436	-3,514,687
Change in Investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash flow from investments	-1,664,174	-523,525	-446,988	-607,400	-211,132	-364,720	-137,975	-125,936	-338,384	0	-135,538	-68,044	-84,462	-192,436	-3,514,687
Financing Activities
Bank loans	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Group/Directors Accounts	570,044	735,563	135,082	-2,817,710	-620,190	2,278,636	1,715,232	-334,624	495,593	235,485	400,613	13,159	292,809	193,123	424
Other Short Term Loans	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long term loans	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hire Purchase and Lease Commitments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
other long term liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
share issue	0	0	0	0	0	0	0	0	0	-6,787	-8,364	-86,053	23,515	0	6,616,742
interest	0	0	-1,146	-9,079	-81,341	-148,506	-82,175	-162,189	-162,439	-153,854	-155,122	-159,961	-169,685	-137,558	-45,657
cash flow from financing	570,044	735,563	133,936	-2,826,789	-701,531	2,130,130	1,633,057	-496,813	333,154	74,844	237,127	-232,855	146,639	55,565	6,571,509
cash and cash equivalents
cash	-433,291	3,350,785	-72,772	1,435,527	1,718,128	149,958	-68,033	251,495	201,075	-24,839	-405,840	752,427	-241,931	182,396	288,170
overdraft	0	0	-98,699	-218,304	-2,010,457	-660,191	-123,529	-244,972	250,762	-143,461	72,454	222,393	-262,017	900,887	2,315,134
change in cash	-433,291	3,350,785	25,927	1,653,831	3,728,585	810,149	55,496	496,467	-49,687	118,622	-478,294	530,034	20,086	-718,491	-2,026,964

Very Low Risk70 - 100

Low Risk50 - 70

Moderate Risk30 - 50

High Risk20 - 30

Very High Risk0 - 20

Get a comprehensive credit check for bell,sons & co.(druggists)limited. Get real-time insights into bell,sons & co.(druggists)limited's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Perform a competitor analysis for bell,sons & co.(druggists)limited by selecting its closest rivals, whether from the MANUFACTURING sector, other large companies, companies in PR9 area or any other competitors across 12 key performance metrics.

BELL,SONS & CO.(DRUGGISTS)LIMITED group structure

Bell,Sons & Co.(Druggists)Limited has no subsidiary companies.

Ultimate parent company

MARKSANS PHARMA LTD

#0061417

MARKSANS HOLDINGS LIMITED

05591744

2 parents

BELL,SONS & CO.(DRUGGISTS)LIMITED

00351951

BELL,SONS & CO.(DRUGGISTS)LIMITED Shareholders

marksans holdings limited

100%

Bell,Sons & Co.(Druggists)Limited currently has 7 directors. The longest serving directors include Mr Mark Saldanha (Jan 2008) and Mr Sathish Konasagar Jayanna (Oct 2016).

officer	country	age	start	end	role
Mr Mark Saldanha	India	52 years	Jan 2008	-	Director
Mr Sathish Konasagar Jayanna	England	51 years	Oct 2016	-	Director
Ms Sandra Saldanha	India	52 years	Mar 2017	-	Director
Mr Jitendra Sharma	India	55 years	Mar 2017	-	Director
Mr Seetharama Buddharaju	England	72 years	May 2020	-	Director
Mr Seetharama Buddharaju	England	72 years	May 2020	-	Director
Mr John Molyneux		47 years	May 2024	-	Director

P&L

March 2024

turnover

53.7m

+17%

operating profit

7.6m

+54%

gross margin

20.4%

+15.45%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

March 2024

net assets

26m

+0.2%

total assets

36.1m

+0.17%

cash

7.1m

-0.06%

net assets

Total assets minus all liabilities

Similar Companies

Agree?

pharmapac (u.k.) limited

g.r. lane health products limited

rsr limited

g. & m. procter limited

3.5

tcs biosciences limited

company number

00351951

Type

Private limited with Share Capital

industry

21100 - Manufacture of basic pharmaceutical products

incorporation date

April 1939

accounts

Full Accounts

ultimate parent company

MARKSANS PHARMA LTD

previous names

N/A

last accounts submitted

March 2024

address

gifford house slaidburn crescent, southport, merseyside, PR9 9AL

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We found 6 charges/mortgages relating to bell,sons & co.(druggists)limited. Currently there are 0 open charges and 6 have been satisfied in the past.

bell,sons & co.(druggists)limited Company Information

bell,sons & co.(druggists)limited Estimated Valuation

bell,sons & co.(druggists)limited Estimated Valuation

bell,sons & co.(druggists)limited Estimated Valuation

Bell,sons & Co.(druggists)limited Overview

Bell,sons & Co.(druggists)limited Health Check

BELL,SONS & CO.(DRUGGISTS)LIMITED financials

bell,sons & co.(druggists)limited Credit Report and Business Information

Bell,sons & Co.(druggists)limited Competitor Analysis

bell,sons & co.(druggists)limited Ownership

bell,sons & co.(druggists)limited directors

bell,sons & co.(druggists)limited company details

bell,sons & co.(druggists)limited Charges & Mortgages

bell,sons & co.(druggists)limited Companies House Filings - See Documents